---
title: "GLP‑1 Receptor Agonists and SGLT2 Inhibitors Linked to Lower Alzheimer Risk in Type 2 Diabetes"
id: "medrxiv-20-glp-1-receptor-agonists-vs-sglt2-inhibitors-for-alzheimer-disease-risk-in-type"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-20-glp-1-receptor-agonists-vs-sglt2-inhibitors-for-alzheimer-disease-risk-in-type"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.22.26358702v1?rss=1"
published_at: "2026-07-24T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# GLP‑1 Receptor Agonists and SGLT2 Inhibitors Linked to Lower Alzheimer Risk in Type 2 Diabetes
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-20-glp-1-receptor-agonists-vs-sglt2-inhibitors-for-alzheimer-disease-risk-in-type
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.22.26358702v1?rss=1)
- **Published At:** 2026-07-24T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- People with **type 2 diabetes mellitus (DM2)** face elevated risk of **Alzheimer disease (AD)**; this systematic review and meta‑analysis evaluated whether glucose‑lowering agents—**GLP‑1 receptor agonists (GLP1RAs)** and **SGLT2 inhibitors (SGLT2i)**—affect incident AD and dementia risk. - The authors searched PubMed, Embase, and Cochrane for randomized controlled trials, cohort, and case‑control studies from January 1, 2006 to April 15, 2025, and identified 12 eligible studies (1 RCT and 11 cohort studies). - The primary outcome was incident **AD and dementia**, measured principally using adjusted hazard ratios (HRs). Secondary outcomes included HbA1c levels and their association with cognitive protection; a regression analysis explored variables explaining observed effects. - Combined evidence showed reduced risk of **AD** (HR 0.72; 95% CI 0.59–0.87) and **dementia** (HR 0.84; 95% CI 0.76–0.92) for users of GLP1RAs and SGLT2i compared with other glucose‑lowering therapies. Heterogeneity was moderate to high and overall certainty was moderate. - In direct comparison, **SGLT2i** exhibited a modest benefit versus **GLP1RAs** for AD protection (reported HR 1.07; 95% CI 1.00–1.14; p = 0.0496) as presented by the authors. - Baseline **HbA1c** was associated with AD risk estimates among **SGLT2i** users but not among **GLP1RAs** users, suggesting a potential interaction with glycemic control for SGLT2i effects. - The authors conclude the findings support the potential of **GLP1RAs** and **SGLT2i** to slow cognitive decline in DM2, with possible dependence on glycemic control and central modulation; the report is a preprint and not peer‑reviewed. - Data used were drawn from publicly available sources; the authors declared no competing interests and stated that study data are available on request.
## Clinical Analysis & Structured Key Points
GLP-1 Receptor Agonists vs SGLT2 Inhibitors for Alzheimer Disease Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis | medRxiv Skip to main content GLP-1 Receptor Agonists vs SGLT2 Inhibitors for Alzheimer Disease Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis View ORCID Profile Levi Leal Silva Sr. , View ORCID Profile Maria Scheffer Valverde , View ORCID Profile Anderson Matheus Silva Sr. , View ORCID Profile Luana DG Braz , View ORCID Profile Kau Kunigami da Silva Sr. , View ORCID Profile Emanuel Medeiros Aguiar Sr. , Vitor Drummond Volta Sr. , View ORCID Profile Clara de Oliveira , View ORCID Profile Rene Rodrigues Alves , View ORCID Profile Filipi Fim Andreao Sr. , View ORCID Profile Carolina Braga Moura , View ORCID Profile Diogo Haddad Santos Sr. doi: https://doi.org/10.64898/2026.07.22.26358702 Levi Leal Silva Sr. 1 Federal University of Rio de Janeiro; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Levi Leal Silva Sr. For correspondence: llealsmb{at}gmail.com Maria Scheffer Valverde 2 Faculty of Medical Sciences and Health; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Maria Scheffer Valverde Anderson Matheus Silva Sr. 3 Federal University of Pernambuco; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Anderson Matheus Silva Sr. Luana DG Braz 1 Federal University of Rio de Janeiro; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Luana DG Braz Kau Kunigami da Silva Sr. 1 Federal University of Rio de Janeiro; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Kau Kunigami da Silva Sr. Emanuel Medeiros Aguiar Sr. 1 Federal University of Rio de Janeiro; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Emanuel Medeiros Aguiar Sr. Vitor Drummond Volta Sr. 1 Federal University of Rio de Janeiro; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Clara de Oliveira 1 Federal University of Rio de Janeiro; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Clara de Oliveira Rene Rodrigues Alves 1 Federal University of Rio de Janeiro; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Rene Rodrigues Alves Filipi Fim Andreao Sr. 1 Federal University of Rio de Janeiro; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Filipi Fim Andreao Sr. Carolina Braga Moura 4 Santa Casa de Sao Paulo; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Carolina Braga Moura Diogo Haddad Santos Sr. 5 University of Sao Paulo Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Diogo Haddad Santos Sr. Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Purpose: People with type 2 diabetes mellitus (DM2) have an increased risk of Alzheimer's Disease (AD). GLP1 receptor agonists (GLP1RAs) and SGLT2 inhibitors (SGLT2i) have emerged as potential interventions to prevent AD and dementia and may provide insights into disease mechanisms. Methods: PubMed, Embase, and Cochrane were searched for randomized controlled trials (RCTs), cohort, and case control studies between January 1, 2006, and April 15, 2025, comparing GLP1RAs and/or SGLT2i in adults with DM2 without cognitive impairment at baseline. A total of 12 studies met the inclusion criteria (1 RCT and 11 cohort studies). The primary outcome was incident AD and dementia, assessed primarily through adjusted hazard ratio (HR). Secondary outcomes were HbA1C levels and their relation to cognitive protection. A regression analysis was performed to assess the variables that could explain the result obtained. Results: GLP1RAs and SGLT2i consistently demonstrated a reduced risk of AD (HR = 0.72; 95% CI, 0.59 to 0.87) and dementia (HR = 0.84; 95% CI, 0.76 to 0.92) compared to other glucose-lowering therapies, with moderate/high heterogeneity and moderate certainty. Also, SGLT2i showed a modest benefit over GLP1RAs in protecting against AD (HR: = 1.07; 95% CI, 1.00 to 1.14; p = 0.0496), and baseline HbA1c was associated with AD risk estimates among SGLT2i users but not among GLP-1RAs users. Conclusion: These findings reinforce the potential of GLP1RAs and SGLT2i as therapeutic options to slow cognitive decline in DM2, possibly depending on glycemic control and central modulation. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study used (or will use) ONLY openly available human data that were originally located at PubMed, Embase and Cochrane. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted July 24, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following GLP-1 Receptor Agonists vs SGLT2 Inhibitors for Alzheimer Disease Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share GLP-1 Receptor Agonists vs SGLT2 Inhibitors for Alzheimer Disease Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis Levi Leal Silva Sr. , Maria Scheffer Valverde , Anderson Matheus Silva Sr. , Luana DG Braz , Kau Kunigami da Silva Sr. , Emanuel Medeiros Aguiar Sr. , Vitor Drummond Volta Sr. , Clara de Oliveira , Rene Rodrigues Alves , Filipi Fim Andreao Sr. , Carolina Braga Moura , Diogo Haddad Santos Sr. medRxiv 2026.07.22.26358702; doi: https://doi.org/10.64898/2026.07.22.26358702 Share This Article: Copy Citation Tools GLP-1 Receptor Agonists vs SGLT2 Inhibitors for Alzheimer Disease Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis Levi Leal Silva Sr. , Maria Scheffer Valverde , Anderson Matheus Silva Sr. , Luana DG Braz , Kau Kunigami da Silva Sr. , Emanuel Medeiros Aguiar Sr. , Vitor Drummond Volta Sr. , Clara de Oliveira , Rene Rodrigues Alves , Filipi Fim Andreao Sr. , Carolina Braga Moura , Diogo Haddad Santos Sr. medRxiv 2026.07.22.26358702; doi: https://doi.org/10.64898/2026.07.22.26358702 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (590) Allergy and Immunology (883) Anesthesia (320) Cardiovascular Medicine (4652) Dentistry and Oral Medicine (464) Dermatology (399) Emergency Medicine (628) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1582) Epidemiology (15585) Forensic Medicine (32) Gastroenterology (1164) Genetic and Genomic Medicine (6855) Geriatric Medicine (707) Health Economics (1027) Health Informatics (4820) Health Policy (1404) Health Systems and Quality Improvement (1681) Hematology (567) HIV/AIDS (1297) Infectious Diseases (except HIV/AIDS) (16123) Intensive Care and Critical Care Medicine (1138) Medical Education (647) Medical Ethics (148) Nephrology (702) Neurology (6981) Nursing (357) Nutrition (1052) Obstetrics and Gynecology (1200) Occupational and Environmental Health (983) Oncology (3489) Ophthalmology (1011) Orthopedics (381) Otolaryngology (430) Pain Medicine (450) Palliative Medicine (135) Pathology (691) Pediatrics (1747) Pharmacology and Therapeutics (720) Primary Care Research (747) Psychiatry and Clinical Psychology (5690) Public and Global Health (9512) Radiology and Imaging (2313) Rehabilitation Medicine and Physical Therapy (1402) Respiratory Medicine (1224) Rheumatology (619) Sexual and Reproductive Health (748) Sports Medicine (564) Surgery (748) Toxicology (105) Transplantation (295) Urology (276)
## Related Clinical Research

- [AD-Smart trial to repurpose diabetes and ADHD drugs for Alzheimer’s patients](https://medichelpline.com/clinical-feed/bmj-0-ad-smart-alzheimer-x2019-s-trial-will-test-diabetes-and-adhd-drugs-on-patients.md)
- [Ultra-processed foods linked to MRI signs of vascular brain injury in middle-aged adults](https://medichelpline.com/clinical-feed/medical-news-today-0-ultra-processed-foods-may-be-harming-brain-health-in-otherwise-healthy-adults.md)
- [Global dementia incidence projected to reach 24.7 million new cases annually by 2050](https://medichelpline.com/clinical-feed/medical-news-today-0-dementia-cases-to-double-by-2050-why-women-some-countries-may-be-at-higher-risk.md)
- [Sex differences in genetic links between modifiable risk factors and Alzheimer’s disease](https://medichelpline.com/clinical-feed/medrxiv-15-sex-differences-in-genetic-liability-to-modifiable-alzheimer-s-disease-risk.md)
- [Education and Alzheimer’s Genetic Risk Do Not Explain GLP-1 RA Associations With Dementia in Type](https://medichelpline.com/clinical-feed/medrxiv-23-education-and-alzheimer-disease-genetic-risk-in-associations-of-glp-1-receptor.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.